Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT05226871 |
| Consolidated Lead Sponsor | Pfizer |
| Therapeutic Condition Cohort | Oncology and Hematology |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | ACTIVE NOT RECRUITING |
| Registered Enrollment | 35 participants (ACTUAL) |
| Registered Start Date | 2022-07-07 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| UCSF Medical Center and Helen Diller Cancer Center | San Francisco, CA | Open Hospital Dossier -> |
| The First Affiliated Hospital of Anhui Medical University | Hefei, China | Open Hospital Dossier -> |
| Beijing Cancer Hospital | Beijing, China | Open Hospital Dossier -> |
| Harbin Medical University Cancer Hospital | Harbin, China | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.